康复患者抗骨质疏松药用药趋势与合理应用评价分析  

Evaluation and analysis of the trend and rational application of anti-osteoporosis drugs in convalescent patients

作　　者：徐嘉路 胡静 XU Jialu;HU Jing(Department of Pharmacy,Shanghai Ruijin Rehabilitation Hospital,Shanghai 200023,China)

机构地区：[1]上海市瑞金康复医院药剂科,上海200023

出　　处：《上海医药》2021年第21期67-71,共5页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:分析我院门诊抗骨质疏松症药的应用情况及未来趋势,为临床合理用药提供参考。方法:回顾性分析我院2017—2019年门诊抗骨质疏松症药的类别品种、销售额、用药频度(DDDs)、限定日费用(DDC)和药物利用指数(DUI)。结果:抗骨质疏松症药的销售额总体平稳,无大幅波动。碳酸钙D3片(Ⅱ,朗迪)的DDDs排序始终保持在首位。鲑降钙素注射液(密钙息)的DDC最高,但呈逐年下降的趋势。DUI≤1.0药物比例由54.55%增加到70.00%。结论:我院抗骨质疏松症药的使用基本合理,药物的选择首先考虑安全性,同时对药效进行监测,再考虑患者的经济状况和医疗成本。Objective:To analyze the application situation and future trend of anti-osteoporosis drugs in outpatient department of our hospital so as to provide reference for clinical rational drug use.Methods:The categories and varieties,sales,medication frequency(DDDs),limited daily cost(DDC)and drug utilization index(DUI)of anti-osteoporosis drugs,which were used from 2017 to 2019 in the outpatient department of our hospital,were retrospectively analyzed.Results:The sales of antiosteoporosis drugs were stable without significant fluctuation.The ranking of calcium carbonate D3 tablets(II,Rondi)had been remained in the first place.The DDC of salmon calcitonin injection(Miacalcium)was on the highest,but decreased year by year.The proportion of drugs with DUI≤1.0 increased from 54.55%to 70.00%.Conclusion:The use of anti-osteoporosis drugs in our hospital is basically reasonable.Safety is the first consideration and then the economic status of patients and medical cost in drug selection and meanwhile efficacy is monitored.

关 键 词：抗骨质疏松症药 用药分析 用药频度 药物利用指数 

分 类 号：R977[医药卫生—药品] R969.3[医药卫生—药学]